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Abstract
Background: The aim of this study was to analyze the significance of leucine to proline substitution at position
138(Leu138Pro) on the hydrolysis of penicillin and ampicillin that we identified in the blaSHV gene of clinical
Escherichia coli swine isolate.
Results: Kinetic analysis of the mutant proteins showed that Km value of the purified L138P mutant was
comparatively higher than SHV-1, SHV-33 and SHV-33(L138P) enzyme for penicillin and ampicillin. Docking
simulation of the SHV-1 and SHV-(L138P) enzymes also confirmed that b-lactamases preferred penicillin to
ampicillin and the SHV-1 had a higher binding affinity for antibiotics compared to the SHV-(L138P) and other
mutants.
Conclusions: Our result demonstrated that L138P has a reduced role in penicillin and ampicillin hydrolyzing
properties of SHV b-lactamases. These naturally occurring mutations rendering reduced function of the existing
protein could trigger the emergence or acquisition of more effective alternative mechanisms for b-lactam
hydrolysis.
Background
Antimicrobial resistance based on hydrolysis of the anti-
biotic by b-lactamases is currently a worldwide problem.
It is one of the single most prevalent mechanisms
responsible for resistance to b-lactams in clinical isolates
of the Enterobacteriaceae [1-3]. Among the four classes
(A to D) of b-lactamases, plasmid mediated class A and
C b-lactamases have been of high clinical concern in
hospital as well as community acquired infections [1,4].
Promiscuous plasmids carrying b-lactamase encoding
genes are described to spread drug resistance among
different groups of microbes under local selection
pressure imposed by the commonly used antibiotics
[1,5,3]. One of the most common plasmid mediated
b-lactamase enzymes is closely related to TEM and SHV
penicillinase [6,3]. Recently CTX-M and AmpC type
b-lactamase are being widely reported from Enterobac-
teriaceae that are associated with nosocomial and
community acquired infections [1,7].
Use of extended-spectrum b-lactam antibiotics has led
to the occurrence of variants of these b-lactamases carry-
ing amino acid substitutions that alter the enzyme’s sub-
strate specificity [1,6,8,9]. SHV-1 is an important plasmid
mediated b-lactamase found in the chromosome of most
strains of Klebsiella pneumonia. Its hydrolytic spectrum
of activity is similar to that of TEM -1, but it shows bet-
ter activity against ampicillin [10,11]. Natural evolution
and appearance of mutations has taken place in response
to an array of different penicillin derivatives, cephamycins
and fourth generation cephalosporins. After identification
of SHV-2, the first plasmid-mediated b-lactamase capable
of hydrolyzing extended-spectrum cephalosporins, several
point mutations in SHV b-lactamase have been reported
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enzyme [8,12-14]. This modification leads to either an
increase in minimum inhibitory concentration (MIC) or
broadens the spectrum of the antimicrobial resistance
observed. Amino acids from the region around the posi-
tion 182 to the catalytic triad do not generally tolerate
substitution in TEM b-lactamase and are thought to be
necessary for proper core packing and catalytic residue
orientation [15,9]. Highly conserved residues on Class A
b-lactamases (Phe 66 and Pro 67) are involved in hydro-
phobic core packing interactions. Likewise Thr 71 and
Lys 73 are important for proper positioning of the cataly-
tic residues Ser 70 and Asn 132 [16,13]. However, the
effect of substitutions on amino-acid residues that alter
the substrate hydrolyzing property of SHV enzyme is still
unknown. The SHV b-lactamases identified in our study
contained a single L138P change compared to wild-type
enzyme SHV-1. Since this mutation occurred naturally in
SHV-1 b-lactamases, we speculated that any changes in
the substrate affinity must be attributed to this single
amino acid substitution. Thus, to gain deeper insight we
performed cloning, expression and enzyme kinetics of
SHV L138P b-lactamase. For uniformity and comparative
study we cloned a wild type blaSHV-1 gene from K. pneu-
moniae into the pET 200 cloning and expression vector.
This plasmid was used as template for creating SHV-33
and target mutant SHV alleles (blaSHV-L138P, blaSHV-33
(L138P)) by site directed mutagenesis. Since SHV-33 has a
single amino-acid substitution in SHV-1 and was pre-
viously identified in our study, we used these known
b-lactamases as control. The phenotypic and enzyme
kinetics results were also verified by a molecular docking
simulation experiment.
Methods
Bacterial strains
E. coli was isolated from the feces of pigs with mixed
clinical signs of digestive and a respiratory disorder was
identified by biochemical tests and by VITEK (Vitek sys-
tem; bioMerieux, Marcy l’Etoile, France). Once identi-
fied, the culture was stored in Tryptic Soy Broth (TSB)
(Difco Laboratories, Detroit, MI) mixed with 20% gly-
cerol (Shinyo Pure Chemicals Co. Ltd., Japan) at -70°C
until use.
Bacterial strains and antimicrobial tests
An E. coli isolated from the feces of pigs with mixed
clinical signs of digestive and a respiratory disorder was
tested with antibiotic susceptibility discs according to
the guidelines of the Clinical and Laboratory Standards
Institute (CLSI) [17]. The active ingredients of the
selected antibiotics were cefotaxime (CTX), ceftazidime
(CAZ), cefoxitin (FOX) and ceftiofur (CEF). The isolate
was further tested by the double disk diffusion tests
using cefotaxime (CTX), ceftazidime (CAZ), cefoxitin
(FOX) in combination with amoxicillin/clavulanic acid
(AMC) (Becton Dickinson, Germany) and Oxoid Ltd.,
UK) [17]. The MICS were determined by micro broth
dilution method for the cephalosporins that showed
complete or decreased inhibition zone diameter in the
disk diffusion test. Performance and evaluation of the
MIC determinations followed the recommendation of
the CLSI [18].
Sequence analysis of the b-lactamases genes
Oligonucleotide primers targeting TEM and SHV b-lac-
tamases and sequencing of the PCR products was per-
formed as described in our previous study [5]. The
search for the homologous sequence was conducted in
the GenBank database using the Basic Local Alignment
Search Tool (BLAST) through the National Center for
Biotechnology Information (NCBI) web site (http://
www.ncbi.nlm.nih.gov/BLAST). Nucleotide substitutions
were analyzed based on information available in http://
www.lahey.org/studies/webt.htm.
Site directed mutagenesis of blaSHV-1 genes
Wild type blaSHV-1 gene from K. pneumoniaew a s
cloned in pET 200 cloning vector. This plasmid was
used as template for generating blaSHV(L138P), blaSHV-33
(P226S) and blaSHV-33(L138P) g e n e sb ys i t ed i r e c t e dm u t a -
genesis following the procedures described by Zheng
et. al [8,19]. Description of the primers used in the
study are listed in Table 1. All the PCR-amplified pro-
ducts were evaluated by agarose gel electrophoresis and
the band with the expected size was extracted using
QIAEX
® II gel extraction kit (Qiagen, Hilden, Germany)
and further treated with 10 U DpnI (New England,
H e r t f o r d s h i r e ,U K )a n di n c u b a t e da t3 7 ° Cf o r3h r s .A n
aliquot of 2 μl of this PCR product was transformed
into TOPO 10 competent cells and plated on Tryptic
Soy Agar (TSA) (Difco Laboratories, Detroit, MI) agar
plate containing 100 μg/ml of kanamycin. A total of 3
colonies were selected and their plasmids were extracted
using mini-prep. Sequences of all these b-lactamases
were confirmed twice by the nucleotide sequencing
using T7 forward and reverse primers.
b-lactamase expression and Western blot
The expression of four different recombinant proteins
encoding in the pET 200 expression vector carrying
blaSHV-1, blaSHV-1(L138P), blaSHV-33 and blaSHV-33(L138P)
genes was carried out in Rossetta-gami (RG) E. coli
cells. The cells pellets harvested by centrifugation were
washed with PBS twice, re-suspended in lysis buffer
(20 mM imidazole) overnight at 4°C and lysed by soni-
cation. The His Spin Trap (GE Healthcare, Buckingham-
shire, UK) were used for elution of the protein by
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lactamases were determined by BCA protein assay kit
(Pierce, Rockford, IL) with bovine serum albumin as
standard [20]. Proteins separated by SDS-PAGE (Mini-
Protean II, Bio-Rad, Hercules, CA, USA) were trans-
ferred to Hybond ECL nitrocellulose membrane (Amer-
sham life Science, Buckinghamshire, UK), and incubated
in anti His mouse IgG followed by rabbit anti mouse
IgG. Binding was detected using an AP conjugate sub-
strate kit (Bio-Rad) according to the manufacture’s
instruction.
Enzyme activity assay
b-lactamase activity was determined by observing the
rate of penicillin and ampicillin hydrolysis at 240 nm
and 235 nm, respectively. Enzyme assay was performed
at 25°C in 1 mM phosphate buffer (pH 7.0) [12]. Spec-
trophotometric measurements were made on Analytic
Jena AG (winASPECT
®, spectroanalytical software)
using 1.0-cm path length cuvette. The values for Km and
Vmax were determined using GraFit 6 (Erithacus Soft-
ware, UK).
Molecular docking simulation
The wild-type structure of SHV (pdb code: 1shv) was
used as a template for molecular modeling. All molecu-
lar modeling simulations were performed by Discovery
Studio 2.5 (Accelrys, USA) and CHARMm forcefield
and CFF partial charge were used for all simulations.
The conformation of L138P position was optimized by
the Dreiding minimization and the molecular dynamics
by standard dynamics cascade protocol was applied to
relax the conformations of the wild-type and L138P
mutant with and default parameters except that produc-
tion steps was 3000 and implicit solvent model was set
to Generalized Born method. Among produced struc-
tures, the most stable structure with the lowest potential
energy was selected as modeled structure for further
docking simulation.
The docking simulations of b-lactamases were con-
ducted by CDOKER module with manually designed
penicillin and ampicillin molecules. Because the active
site and catalytic residues of SHV and TEM lactamasese
are highly conserved, the structure of TEM with bound
penicillin G (pdb code: 1fqg) was used as a reference
structure to identify the initial binding site of penicillin
and ampicillin in the wild-type and L138P lactamases.
Once docking complexes of lactamases and antibiotics
were predicted by CDOCKER module, productive dock-
ing structures of the carbonyl carbon of b-lactam ring
of penicillin and ampicllin directly oriented to the OH
group of catalytic S70 of b-lactamases (for nucleophilic
attack of S70) were considered further binding energy
calculation (Figure 1). The binding energies of the wild-
type and L138P lactamases toward penicillin and ampi-
cillin were calculated using Calculate Binding Energies
protocol with default parameters except that ligand
minimization were performed to consider the flexibility
of residues within binding sites and implicit solvent
model was set to Generalized Born method.
Results
Antimicrobial resistance phenotype and genotype
E. coli 485 exhibited resistance to the commonly used
antimicrobial agents on farms. The Disk diffusion test
showed reduced inhibition zone diameter to cefotaxime
(CTX), ceftazidime(CAZ), ceftiofur (CEF) but not to
cefoxitin (FOX). This strain exhibited >5 mm increase
in inhibition zone diameter of both cefotaxime and cef-
tazidime in the presence of amoxicillin/clavulanic acid
(AMC) in contrast to when the antibiotics were tested
alone. RG E. coli cells carrying blaSHV-1, blaSHV-(L138P),
blaSHV-33 and blaSHV-33(L138P) exhibited variable zone
diameter to penicillin and ampicillin in the disk diffu-
sion test. No decrease in zone diameter was noticed for
cefotaxime (CTX), ceftazidime(CAZ), ceftiofur (CEF)
and cefoxitin (FOX). The MIC values for all E. coli
strains are listed in table 2. Genotype analysis of E. coli
isolate showed TEM and SHV b-lactamase genes
showed 100% identity to blaTEM-20 and blaSHV-1 genes
except at position 138 where leucine (L) to proline (P)
polymorphism was detected.
Table 1 Primers used for detection of TEM and SHV b-lactamases and for site directed mutagenesis in this study
Targets Primer Sequence (5’-3’) Product
size(bp)
Annealing
temp
Gene bank
Accession
no.
TEM TEM-F TEM-R TCG GGG AAA TGT GCG TGC TTA ATC AGT GAG GCA CC 1074 62 AM849806
SHV SHV-F SHV-R GCC GGG TTA TTC TTA TTT GTC GC ATG CCG CCG CCA GTC A 1016 62 EU342351
SHV-M
a SHV-MF SHV-MR C AAT CTG CCG CTG GCC ACC GTC GGC GGC CAG CGG CAG ATT GGC GGC GCT
G
52 -
SHV-
33
b
SHV-33F SHV-
33R
GTG CTG TCT GCG GGC TGG TTT ATC GCC CGC AGA CAG CAC GGA GCG GAT C 52 -
a:primer used to create the mutation L138P in SHV-1 b-lactamase identified in this study.
b:primer used to create a single mutation P226S (SHV-33 b-lactamase).
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After cloning and confirmation of blaSHV-1 genes in the
pET 200 cloning and expression vector, reverse muta-
tion at single point (L138P) was successfully performed
by site directed mutagenesis to generate blaSHV-(L138P).
Plasmid carrying blaSHV-1 gene was used to generate
another mutation (S226P) that showed complete identity
to blaSHV-33 gene. Sequence analysis also showed that
the final site directed mutagenesis on the plasmid carry-
ing blaSHV-33 gene, gave rise to the blaSHV-33(L138P).
Cloning, expression and b-lactamase activity assay
All four pET 200 cloning and expression vectors carrying
blaSHV-1, blaSHV-1(L138P), blaSHV-33 and blaSHV-33(L138P)
genes expressed in Rossetta-gami E. coli cells. Expressed
proteins matched the size of 32.22 kDa in SDS-PAGE
and Western blot. Enzyme kinetics showed that SHV b-
lactamases cloned and expressed in this study exhibited
variable catalytic activity of penicillin and ampicillin. Km
value for both penicillin ampicillin was lowest for SHV-1
b-lactamase followed by SHV-33, SHV-33(L138P) and
SHV-L138P. The description of the Km, kcat and kcat/Km
values are given are listed in table 3.
Molecular docking simulation of SHV lactamases
The structures of the wild-type and L138P mutant were
prepared by molecular dynamics. The alpha helix of
L138P mutant including 138 position was shorter than
that of the wild-type and the orientation of the catalytic
residues were slightly changed due to the proline muta-
tion (Figure 2). The productive docking structures with
the lowest binding energies predicted by Discovery Stu-
dio 2.5 were selected as binding structures of penicillin
and ampicillin (Figure 3). The wild-type showed higher
binding affinity (lower binding energy) of both penicillin
(16.5 kcal/mol) and ampicillin (31.2 kcal/mol) than the
L138P mutant, confirming that the L138P mutant had
poor binding affinity (higher Km) of penicillin (19.4 kcal/
mol) and ampicillin (36.3 kcal/mol) compared to the
wild-type. The wild-type and L138P mutant had lower
binding energies of penicillin (16.5 and 19.4 kcal/mol
respectively) over ampicillin (31.2 and 36.3 kcal/mol
respectively), consistent with experimental results that
both b-lactamases preferred penicillin to ampicillin.
Discussion
Extensive research on b-lactam resistance has been car-
ried among the clinical hospital isolates and majority of
b-lactamases reported to date have been derived from
clinical isolates of humans. However, recent research
has shown the increasing occurrence of b-lactam






Figure 1 Structures of penicillin G (A) and ampicillin (B).
Table 2 Phenotype and genotype of b-lactamases for the E. coli field isolate and mutants included in the study
Inhibition Zone diameter (mm)/MICs (mg/L)
a b-lactamases
Strains AM PEN CEF FOX CAZ CTX SHV TEM
E. coli ≤1/640 ≤1/640 8/320 15/20 11/160 12/320 SHV-1(L138P) TEM-20
RG E. coli-M1 12/160 1/40 - - - - SHV-1
RG E. coli-M2 28/40 14/40 - - - - L138P
RG E. coli-M3 11/160 1/160 - - - - P226S
RG E. coli-M4 28/20 12/2 - - - - L138P P226S
aAmpicillin (AM), penicillin (PEN), ceftiofur (CEF), cefoxitin (FOX), ceftazidime (CAZ), cefotaxime (CTX).
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mal derived E. coli and Salmonella, which are related to
community acquired infections and food safety [1,5,21].
In continuation of our study effort to address some of
these issues of antimicrobial resistance in Enterobacter-
iaceae isolated from farm animals, our study focused on
the identification and understanding the dynamics of
unique blaSHV-L138P mutation observed in E. coli isolated
from swine.
Phenotypic antimicrobial tests showed that the E. coli
isolate was resistant to the common antimicrobial agents
used in farms and also exhibited reduced sensitivity to
three indicator cephalosporins included in the study.
Genetic analysis showed the presence of both TEM-20
and SHV b-lactamases that differed from SHV-1 only by
a single amino acid substitution leucine to proline at
position 138. This mutation was of special interest as
SHV b-lactamses are specially related to K. pneumoniae
and we wanted to see if this blaSHV gene with single
amino-acid substitution (L138P) detected in E. coli
added to its substrate hydrolyzing activity [1,2,4,22,23].
All the cloned blaSHV genes expressed the specific
protein bands that were confirmed by SDS-PAGE and
Western blot. The size of the expressed SHV b-lacta-
mases was larger than reported in previous research
because of the intact 23 amino acid pro-peptide and His
tag [20]. The enzyme kinetics of all the expressed b-lac-
tamases showed differences in the affinities for penicillin
and ampicillin that were included in this experiment
(Table 3). The narrow spectrum b-lactamases SHV-1
and SHV-33 exhibited higher affinity to penicillin and
ampicillin respectively, whereas SHV-1 and SHV-33
with only in one amino acid (L138P) mutation exhibited
reduced activity for both the substrate used in study.
This indicated that leucine at position 138 was impor-
tant for SHV b-lactamase and played an important role
in hydrolyzing penicillin and ampicilin.
Previous experiments on SHV b-lactamases have
reported three natural mutations at position 69, 130 and
187 to be involved in conferring resistance to the inhibi-
tors [11-13]. Proline has stronger stererochemical con-
straints than any other residues, with only one instead
of two variable backbone angles and it lacks the normal
amine backbone for hydrogen bonding. This could have
the disruptive function to regular secondary structure
and decreased the length of a-helix and changed the
orientation of residues of binding sites. Based on the
modeled docking structures of the wild-type and L138P
mutant, the wild-type had three hydrogen bonds with
penicillin and ampicillin but the L138P mutant had two
hydrogen bonds, indicating that these structural changes
by L138P mutation may decrease the substrate binding
and finally resulted in reduced activity of L138P mutant.
This result was supported by higher Km value for peni-
cillin and ampicillin of L138P mutation when inserted
in SHV-1 and SHV-33.
Conclusions
Based on our results we concluded that this mutation
caused a drop in hydrolyzing penicillin and ampicillin.
Table 3 Kinetics parameters for penicillin and ampicillin
penicillin ampicillin
Enzymes Km
(μM)
Kcat
(s
-1)
Kcat/Km
(μM
-1s
-1)
Km
(μM)
Kcat
(s
-1)
Kcat/Km
(μM
-1s
-1)
SHV-1 49 1460 29.79 26 5910 227.3
SHV-1(L138P) 76 3370 4.43 87 1363 15.66
SHV-33 59 2140 36.27 16 1375 85.93
SHV33-L138P 91 2680 29.45 90 1503 16.7






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Figure 2 Structure of the wild-type (A) and L138P b-lactamases
(B). The red and blue residues indicate the catalytic residues (S70-
K73-S130-E166) and mutation site (L138P), respectively.
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these antimicrobials, naturally occurring L138P muta-
tion in the conserved region of blaSHV gene was
expected to increase substrate hydrolyzing property or
widen the substrate spectrum of SHV- b-lactamases.
However, adverse effect of this mutation observed on its
substrate hydrolyzing properties may be a way these
microbes trigger emergence or acquisition of more
effective alternative mechanisms. Our speculation is in
line with recent reports on CTX-M and AmpC b-lacta-
mases that have more frequently been reported than the
classical TEM and SHV b-lactamase from farm and
food materials [1,3,4,7,21].
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